

Anti-PD1-IL2v Fusion hIgG1 Antibody(2149)

Product information

GM-88264AB-10	10 µg
GM-88264AB-100	100 µg
GM-88264AB-1000	1 mg

Antibody Information

Species Reactivity	Human;
Clone	2149
Source/Isotype	hIgG1 (KDEL,L234A/L235A /N297A), Kappa
Application	Activation assay
Specificity	Detects PD1&IL2RA
Gene	PD1&IL2RA
Other Names	PD1: NACP, PARK1, PARK4, SNCA IL2RA, IL2R α
Gene ID	PD1 (6622)
Background	The PD-1/PD-L1 pathway inhibits T cell activity to maintain immune tolerance and block tumor immune escape; relatively, IL-2/IL-2R is a key growth factor in the initial activation phase, promoting T cell proliferation with functional maintenance. In tumor microenvironment, inhibition of PD-1/PD-L1 may reduce the production and response of IL-2, impair amplification and memory formation; The signal intensity of IL-2R affects the reactivation sensitivity of inhibited T cells and the maintenance of anti-tumor effect. IL-2R promotes proliferation versus survival via JAK-STAT (especially Stat5) , whereas PD-1 inhibits TCR/JAK-STAT via Shp-2, possibly attenuating the balance of amplification of IL-2R signaling versus functional differentiation. This coupling suggests that simultaneous enhancement of IL-2/IL-2R signaling in combination therapy synergistically elevates the reactivation of suppressed T cells with the formation of durable antitumor memory.
Storage	Store at 2-8°C short term (1-2 weeks).Store at \leq -20°C long term. Avoid repeated freeze-thaw.
Formulation	20 mM Histidine, 100 mM NaCl, pH 6.0
Endotoxin	< 1 EU/mg, determined by LAL gel clotting assay

Version:3.3

Data Examples

Activation assay

Anti-PD1-IL2v Fusion hIgG1 Antibody(2149) (Catalog # GM-88264AB)
activates the H_CD25 CD122 CD132 Reporter Jurkat(hPD1 OE) Cell Line,
leading to induced luminescence. The EC50 for this effect is 1.578 nM.

H_CD25 CD122 CD132 Reporter Jurkat(hPD1 OE) Cell Line




Fig. assay